PMID- 30008894
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 1792-1074 (Print)
IS  - 1792-1082 (Electronic)
IS  - 1792-1074 (Linking)
VI  - 16
IP  - 2
DP  - 2018 Aug
TI  - Prediction and identification of human leukocyte antigen-A2-restricted cytotoxic 
      T lymphocyte epitope peptides from the human papillomavirus 58 E7 protein.
PG  - 2003-2008
LID - 10.3892/ol.2018.8875 [doi]
AB  - Persistent infection with high-risk human papilloma virus (HPV) is the primary 
      cause of cervical intraepithelial neoplasia (CIN) and cervical carcinoma. HPV58 
      is the third most common HPV genotype in China after HPV16 and HPV18. HPV E6 and 
      E7 are oncoproteins and are constitutively expressed in HPV-associated cancer 
      cells, therefore they are considered to be ideal target antigens for 
      immunotherapy, including HPV therapeutic vaccine. In the present study, human 
      leukocyte antigen (HLA)-A2-restricted cytotoxic T lymphocyte (CTL) epitope 
      peptides were predicted and screened from HPV58 E7 antigen and their 
      immunogenicity was subsequently determined. A total of 6 HLA-A2-binding peptides 
      derived from HPV58 E7 were predicted and selected using 3 different prediction 
      programs. A negative control peptide and PBS were used as two negative controls. 
      Peripheral blood mononuclear cells (PBMCs) with HLA-A2(+) allele were used to 
      detect the specific cellular immune response among the 6 predicted peptides by 
      enzyme-linked immunospot assay (ELISOPT). Following preliminary screening for the 
      predicted peptides, the antigenicity of the peptide HPV58 E7(72-80) was further 
      assessed by an immunoassay to a vaccine contained HPV58 E7 antigen. Specific 
      humoral and cellular immunity were detected using the peptide HPV58 E7(72-80) as 
      the specific antigen. A total of 6 peptides from HPV58 E7 protein were predicted 
      and subsequently named P1 (E7(7-15): TLREYILDL), P2 (E7(14-22): DLHPEPTDL), P3 
      (E7(69-77): CINSTTTDV), and P4 (E7(72-80): STTTDVRTL), P5 (E7(79-87): TLQQLLMGT) 
      and P6 (E7(83-91): LLMGTCTIV). In the ELISPOT assay on HLA-A2 (+) human PBMCs, 
      interferon (IFN)-gamma-production was evident in the P2 and P4 groups. The average 
      numbers of IFN-gamma associated spots in the P2 and P4 groups was 50.61+/-5.37 
      spot-forming cells (SFC)/1x10(5) and 266+/-34.42 SFC/1x10(5), respectively. The 
      numbers of spots in the two peptides were significantly increased compared with 
      the other 4 peptides and the control groups (P<0.05). In the further antigenicity 
      verification of P4 (HPV58 E7(72-80)), the peptide only stimulated the humoral 
      immune response of the AD-HPV16/18/58 mE6E7 vaccine containing HPV58 E7 antigen. 
      Compared with the 2 negative control groups (1:400), the antibody titers of the 
      vaccine group (1:25,600) were significantly increased (P<0.05). In cellular 
      immunoassays the average number of IFN-gamma associated spots was 143.3+/-32.13 
      SFC/1x10(5) in the vaccine group, which was significantly enhanced compared with 
      the PBS group (8+/-5.29 SFC/1x10(5); P<0.01) and the AD-NC group (28+/-5.13 
      SFC/1x10(5); P<0.01). The peptide HPV58 E7(72-80) (STTTDVRTL) displayed 
      sufficient antigenicity to a vaccine contained HPV58 E7 antigen. Therefore, HPV58 
      E7(72-80) peptide may be considered as a candidate epitope peptide for the 
      construction of HPV58 peptide vaccines.
FAU - Wang, He
AU  - Wang H
AD  - Gynecologist Tumor Department, Affiliated Tumor Hospital of Guangxi Medical 
      University, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China.
FAU - Chen, Lilai
AU  - Chen L
AD  - Gynecologist Tumor Department, Affiliated Tumor Hospital of Guangxi Medical 
      University, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China.
FAU - Ma, Weihong
AU  - Ma W
AD  - Gynecologist Tumor Department, Affiliated Tumor Hospital of Guangxi Medical 
      University, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China.
FAU - Zeng, Yue
AU  - Zeng Y
AD  - Gynecologist Tumor Department, Affiliated Tumor Hospital of Guangxi Medical 
      University, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China.
FAU - Qin, Lu
AU  - Qin L
AD  - Gynecologist Tumor Department, Affiliated Tumor Hospital of Guangxi Medical 
      University, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China.
FAU - Chen, Mengjie
AU  - Chen M
AD  - Gynecologist Tumor Department, Affiliated Tumor Hospital of Guangxi Medical 
      University, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China.
FAU - Li, Li
AU  - Li L
AD  - Gynecologist Tumor Department, Affiliated Tumor Hospital of Guangxi Medical 
      University, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20180601
PL  - Greece
TA  - Oncol Lett
JT  - Oncology letters
JID - 101531236
PMC - PMC6036542
OTO - NOTNLM
OT  - E7 epitope peptide
OT  - enzyme linked immunosorbent assay
OT  - enzyme-linked immunospot
OT  - human papillomavirus
EDAT- 2018/07/17 06:00
MHDA- 2018/07/17 06:01
PMCR- 2018/06/01
CRDT- 2018/07/17 06:00
PHST- 2017/08/15 00:00 [received]
PHST- 2018/05/03 00:00 [accepted]
PHST- 2018/07/17 06:00 [entrez]
PHST- 2018/07/17 06:00 [pubmed]
PHST- 2018/07/17 06:01 [medline]
PHST- 2018/06/01 00:00 [pmc-release]
AID - OL-0-0-8875 [pii]
AID - 10.3892/ol.2018.8875 [doi]
PST - ppublish
SO  - Oncol Lett. 2018 Aug;16(2):2003-2008. doi: 10.3892/ol.2018.8875. Epub 2018 Jun 1.